POPeder S. Olofsson

Peder S. Olofsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peder S. Olofsson has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Proliferation of activated hepatic stellate cells requires REST

    by Vladimir S. Shavva, L. Tarnawski, W. Dai, N. Moruzzi, A.-S. Haller, F. Borg, S. Hansson, Q. Guo, M. Cai, E. Fekete, et al.

  • Open Access

    Neuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational Prospects

    by Qi Guo, Peter Holicek, Laura Tarnawski, Peder S. Olofsson

    Purpose of Review: Peripheral nerves are increasingly recognized as regulators of vascular pathology, shaping arterial tone, inflammation, and structural remodeling. This review delineates how neural circuits interface with the aortic wall, considers sympathetic and sensory pathways in atherosclerosis and aneurysm pathophysiology, and discusses emerging experimental approaches and therapeutic strategies. Recent Findings: Autonomic and sensory neural circuits are increasingly recognized as modulators of arterial disease. In experimental atherosclerosis, neuroimmune crosstalk shapes vascular inflammation and influences plaque stability. Limited available evidence from human and experimental studies suggest increased sympathetic innervation within aneurysm tissue. In preclinical models, aneurysm remodeling was linked with sympathetic input, and interventions that reduce noradrenergic signaling via sympathetic denervation or pharmacological adrenergic blockade attenuated disease severity. Improved understanding of the role for innervation in vascular pathophysiology may open therapeutic opportunities, including neuromodulation and pharmacological interventions. Clarifying sources of heterogeneity between models and clinical data can potentially refine therapeutic targets and patient selection, and advance opportunities for precision interventions. Summary: Peripheral neural circuits are integral to vascular homeostasis in health and disease, interfacing with blood vessels and regulating their physiology. Converging human and preclinical evidence implicates sympathetic innervation in disease development, and that dampening adrenergic signaling via denervation or adrenergic blockade may mitigate disease progression. This review discusses mechanistic neuroimmune crosstalk across atherosclerosis and aneurysm biology and outlines some potential translational opportunities. Together, the advances position neurovascular crosstalk as a potentially tractable axis for disease-modifying interventions.

  • Open Access

    Lymphocyte Antigen 6G Mediates Vagotomy‐Associated Reduction in Body Weight

    by Ting Liu, April S. Caravaca, Min Cai, Wanmin Dai, Jérômine Jeanne Vacquié, Qi Guo, Peter Holicek, Maxime Villet, Patricia Teixeira Mendes, Yuyang Zhang, et al.

    Dysregulation of adipocyte function is an important component of metabolic and cardiovascular diseases. It is increasingly evident that interorgan neuroimmune crosstalk in adipose tissue maintains adipose tissue functionality, yet the molecular mechanisms are incompletely understood. The vagus nerve regulates numerous physiological functions, including inflammation and weight control, even in tissues lacking direct cholinergic innervation. In this study, we examined whether vagal signaling is involved in maintaining baseline homeostasis in epididymal white adipose tissue (eWAT) by investigating how disrupting vagus signaling affects adipose tissue physiology. As expected, vagotomized male animals had lower body weight and epididymal white adipose tissue mass as compared with controls. Vagotomized animals showed increased Ly6G + cell infiltration in eWAT. Interestingly, vagotomy‐associated weight loss was significantly attenuated in neutrophil‐deficient Ly6G cre Mcl1 fl/fl mice and in mice treated with repeated injections of anti‐Ly6G antibodies. Together, these observations indicate that there is a Ly6G‐mediated vagotomy‐associated reduction in weight and reveal that Ly6G + cells participate in the regulation of eWAT energy homeostasis.

  • Open Access

    Proliferation of activated hepatic stellate cells requires REST

    by Vladimir S Shavva, L. Tarnawski, W. Dai, N. Moruzzi, A.-S. Haller, F. Borg, S. Hansson, Q. Guo, M. Cai, E. Fekete, et al.

    Background: Activation of hepatic stellate cells (HSCs) is key in liver regeneration and the pathogenesis of chronic liver diseases, such as metabolic dysfunction-associated steatohepatitis (MASH). Activated HSCs promote liver inflammation and fibrosis which can lead to the development of liver cancer. Targeted removal of activated HSCs has shown promise in preventing liver fibrosis and liver cancer in mouse models. HSC activation is characterized by increased mitochondrial metabolism and upregulation of pro-fibrotic genes, but the underlying regulatory mechanisms remain incompletely understood. Since RE1-silencing transcription factor (REST) is known to regulate cell fate and metabolism, we investigated its involvement in HSC activation. Methods: REST-dependent mechanisms of HSC activation were studied using siRNA-mediated REST knock down in primary human HSCs and human HSC-like LX2 cells. Results: Knock down of REST in primary human HSCs and HSC-like LX2 cells reduced proliferation, promoted lipid accumulation and autophagy, and impaired mitochondrial metabolism, resulting in reduced growth. The effects were linked with REST-dependent regulation of the PI3K/AKT/mTORC1 pathway. Conclusions: Our findings identify a REST-dependent mechanism of HSC activation that is important for their activation and proliferation.


  • Open Access

    Author Correction: Neuroimmune cardiovascular interfaces control atherosclerosis

    by Sarajo K. Mohanta, Li Peng, Yuanfang Li, Shu Lu, Ting Sun, Lorenzo Carnevale, Marialuisa Perrotta, Zhe Ma, Benjamin Förstera, Karen Stanic, et al.

  • Open Access

    Survival and Proliferation of Activated Hepatic Stellate Cells Requires REST

    by Vladimir Shavva, Laura Tarnawski, Wanmin Dai, Noah Moruzzi, Anne-Sophie Haller, Filip Borg, Simon Hansson, Qi Guo, Min Cai, Erna Fekete, et al.

    The activation of hepatic stellate cells (HSCs) is a key driver of liver fibrosis and inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). Targeting activated HSCs has shown promise in preventing liver fibrosis and cancer in mouse models. HSC activation is characterized by increased mitochondrial metabolism and upregulation of pro-fibrotic genes. Since RE1-silencing transcription factor (REST) is known to regulate cell fate, metabolism, and survival, we investigated its involvement in HSC activation. We observed reduced Rest mRNA levels in mouse activated HSCs as compared with mouse quiescent HSCs. In primary human HSCs and HSC-like LX2 cells, REST knock-down led to decreased expression of pro-fibrogenic markers and was essential for the survival and proliferation of activated human HSCs in vitro . REST knock-down also promoted lipid accumulation, impaired mitochondrial metabolism, and increased AMPK phosphorylation and autophagy, resulting in reduced growth. Our findings identify a REST-dependent mechanism of HSC activation that is important for their survival and proliferation.

  • Open Access

    Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease

    by Osman Ahmed, Vladimir S. Shavva, Laura Tarnawski, Wanmin Dai, Filip Borg, Viggo V. Olofsson, Ting Liu, Peter Saliba‐Gustafsson, Christian Simini, Matteo Pedrelli, et al.

    Background and objectives: Statins are used for metabolic dysfunction‐associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin‐like phospholipase domain containing 3 (PNPLA3) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early liver steatosis are thus difficult to study.Methods: Liver biopsies were collected from 261 patients without known liver disease at surgery and stratified based on statin use and criteria for the metabolic syndrome (MS). Genotypes and transcript levels were measured using Illumina and Affymetrix arrays, and metabolic and lipoprotein profiles by clinical assays. Statin effects on PNPLA3, de novo lipogenesis (DNL), and lipid accumulation were further studied in vitro.Results: The PNPLA3I148M genetic variant was associated with significantly lower hepatic levels of cholesterol synthesis‐associated transcripts. Patients with MS had significantly higher hepatic levels of MASLD and lipogenesis‐associated transcripts than non‐MS patients. Patients with MS on statin therapy had significantly higher hepatic levels of PNPLA3, acetyl‐CoA carboxylase alpha, and ATP citrate lyase, and statin use was associated with higher plasma fasting glucose, insulin, and HbA1c. Exposure of hepatocyte‐like HepG2 cells to atorvastatin promoted intracellular accumulation of triglycerides and lipogenesis‐associated transcripts. Atorvastatin‐exposure of HepG2, sterol O‐acyltransferase (SOAT) 2‐only‐HepG2, primary human hepatic stellate, and hepatic stellate cell‐like LX2 cells significantly increased levels of PNPLA3 and SREBF2‐target genes, whereas knockdown of SREBF2 attenuated this effect.Conclusions: Collectively, these observations suggest statin‐associated regulation of PNPLA3 and DNL in liver. The potential interaction between PNPLA3 genotype and metabolic status should be considered in future studies in the context of statin therapy for MASLD.


  • Open Access

    Cholinergic signaling in adipose tissue

    by Vladimir S. Shavva, Laura Tarnawski, Ting Liu, Osman Ahmed, Peder S. Olofsson


  • Open Access

    Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult

    by Giada Di Nunzio, Sanna Hellberg, Yuyang Zhang, Osman Ahmed, Jiawen Wang, Xueming Zhang, Hanna M. Björck, Veronika Chizh, Ruby Schipper, Hanna Aulin, et al.

    Apolipoprotein-B (APOB)-containing lipoproteins cause atherosclerosis. Whether the vasculature is the initially responding site or if atherogenic dyslipidemia affects other organs simultaneously is unknown. Here we show that the liver responds to a dyslipidemic insult based on inducible models of familial hypercholesterolemia and APOB tracing. An acute transition to atherogenic APOB lipoprotein levels resulted in uptake by Kupffer cells and rapid accumulation of triglycerides and cholesterol in the liver. Bulk and single-cell RNA sequencing revealed a Kupffer-cell-specific transcriptional program that was not activated by a high-fat diet alone or detected in standard liver function or pathological assays, even in the presence of fulminant atherosclerosis. Depletion of Kupffer cells altered the dynamic of plasma and liver lipid concentrations, indicating that these liver macrophages help restrain and buffer atherogenic lipoproteins while simultaneously secreting atherosclerosis-modulating factors into plasma. Our results place Kupffer cells as key sentinels in organizing systemic responses to lipoproteins at the initiation of atherosclerosis.


  • Open Access

    Hepatic stellate cell activation markers are regulated by the vagus nerve in systemic inflammation

    by Osman Ahmed, April S. Caravaca, Maria Crespo, Wanmin Dai, Ting Liu, Qi Guo, Magdalena Leiva, Guadalupe Sabio, Vladimir S. Shavva, Stephen G. Malin, et al.

    Background: The liver is an important immunological organ and liver inflammation is part of the pathophysiology of non-alcoholic steatohepatitis, a condition that may promote cirrhosis, liver cancer, liver failure, and cardiovascular disease. Despite dense innervation of the liver parenchyma, little is known about neural regulation of liver function in inflammation. Here, we study vagus nerve control of the liver response to acute inflammation. Methods: Male C57BL/6 J mice were subjected to either sham surgery, surgical vagotomy, or electrical vagus nerve stimulation followed by intraperitoneal injection of the TLR2 agonist zymosan. Animals were euthanized and tissues collected 12 h after injection. Samples were analyzed by qPCR, RNAseq, flow cytometry, or ELISA. Results: Hepatic mRNA levels of pro-inflammatory mediators Ccl2, Il-1β, and Tnf-α were significantly higher in vagotomized mice compared with mice subjected to sham surgery. Differences in liver Ccl2 levels between treatment groups were largely reflected in the plasma chemokine (C–C motif) ligand 2 (CCL2) concentration. In line with this, we observed a higher number of macrophages in the livers of vagotomized mice compared with sham as measured by flow cytometry. In mice subjected to electrical vagus nerve stimulation, hepatic mRNA levels of Ccl2, Il1β, and Tnf-α, and plasma CCL2 levels, were significantly lower compared with sham. Interestingly, RNAseq revealed that a key activation marker for hepatic stellate cells (HSC), Pnpla3, was the most significantly differentially expressed gene between vagotomized and sham mice. Of note, several HSC-activation associated transcripts were higher in vagotomized mice, suggesting that signals in the vagus nerve contribute to HSC activation. In support of this, we observed significantly higher number of activated HSCs in vagotomized mice as compared with sham as measured by flow cytometry. Conclusions: Signals in the cervical vagus nerve controlled hepatic inflammation and markers of HSC activation in zymosan-induced peritonitis.